Skip NavigationSkip to Content
Return Return to Search Results

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

  1. Author:
    Pinto, L. A.
    Viscidi, R.
    Harro, C. D.
    Kemp, T. J.
    Garcia-Pineres, A. J.
    Trivett, M.
    Demuth, F.
    Lowy, D. R.
    Schiller, J. T.
    Berzofsky, J. A.
    Hildesheim, A.

  2. Author Address

    NCI, HPV Immunol Lab, SAIC Frederick, Frederick, MD 21702 USA. Johns Hopkins Univ, Baltimore, MD 21218 USA. Informat Management Serv Inc, Silver Spring, MD USA. NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA. NCI, Vaccine Branch, NIH, Bethesda, MD 20892 USA. NIH, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.;Pinto, LA, NCI, HPV Immunol Lab, SAIC Frederick, Frederick Bldg 469,Room 120, Frederick, MD 21702 USA.;lpinto@ncifcrf.gov
    1. Year: 2006
    2. Date: Sep
  2. Journal: Virology
    1. 353
    2. 2
    3. Pages: 451-462
  4. Type of Article: Article
  5. ISSN: 0042-6822
  1. Abstract:

    Human papillomavirus-like particles (HPV VLP) are candidate vaccines that have shown to be efficacious in reducing infection and inducing robust antiviral immunity. Neutralizing antibodies generated by vaccination are largely type-specific, but little is known about the type-specificity of cellular immune responses to VLP vaccination. To determine whether vaccination with HPV-16 L1VLP induces cellular immunity to heterologous HPV types (HPV-18, HPV-31, and HPV-53), we examined proliferative and cytokine responses in vaccine (n=11) and placebo (n=5) recipients. Increased proliferative and cytokine responses to heterologous types were observed postvaccination in some individuals. The proportion of women responding to heterologous types postvaccination (36%-55%) was lower than that observed in response to HPV-16 (73%). Response to HPV-16 VLP predicted response to other types. The strongest correlations in response were observed between HPV-16 and HPV-31, consistent with their phylogenetic relatedness. In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes. (c) 2006 Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.virol.2006.06.021
  3. View record in Web of Science®
  4. WOS: 000240930900020

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel